Anti-Diabetic Therapy in Patients with Hypertension and Liver Disease: A Narrative Review of Integrated Therapeutic Perspectives

Abstract

The comorbidity that is also known as the co-occurrence of chronic diseases is a subject that has become a dominant topic in the global population health discussion. Some of the most common and clinically significant comorbid conditions include diabetes mellitus (DM), hypertension, and liver disease, particularly, non-alcoholic fatty liver disease (NAFLD). These diseases usually have common etiological risk factors and are co-occurring, thus a large burden on health-care systems across the globe. The current prevalence of type 2 diabetes mellitus (T2DM) is more than 500 million worldwide. Insulin resistance is one of the distinguishing features of T2DM and this predisposes individuals to numerous complications. Hypertension is the most common comorbidity among patients with diabetes, which is present in about 50-80 percent of them. The presence of diabetes and hypertension exacerbates the risk of cardiovascular disease, cerebral events, kidney damage, and early death significantly, thus making the successful treatment of this two-fold pathology a top clinical goal. The liver disease, especially NAFLD, is very common in people who are diabetic. Epidemiological research estimates a figure of 70 3/4th percentage of T2DM patients to show hepatic steatosis. There is a spectrum of NAFLD, including the simple steatosis and non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and cirrhosis, which can eventually lead to liver failure. Together, this triad significantly increases the morbidity, morbidity and the general burden on health-care resources. The use of early preventive measures, which involve lifestyle change, weight control, and combined therapeutic options, are invaluable in terms of risk reduction and the improvement of long-term outcomes.